Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy of renal cell carcinoma.
Gouttefangeas C, Stenzl A, Stevanović S, Rammensee HG. Gouttefangeas C, et al. Among authors: stevanovic s. Cancer Immunol Immunother. 2007 Jan;56(1):117-28. doi: 10.1007/s00262-006-0172-4. Epub 2006 May 5. Cancer Immunol Immunother. 2007. PMID: 16676181 Free PMC article. Review.
Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.
Rausch S, Gouttefangeas C, Hennenlotter J, Laske K, Walter K, Feyerabend S, Chandran PA, Kruck S, Singh-Jasuja H, Frick A, Kröger N, Stevanović S, Stenzl A, Rammensee HG, Bedke J. Rausch S, et al. Among authors: stevanovic s. Eur Urol Focus. 2019 Jul;5(4):604-607. doi: 10.1016/j.euf.2017.09.009. Epub 2017 Oct 4. Eur Urol Focus. 2019. PMID: 28988765 Clinical Trial.
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.
Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S. Dengjel J, et al. Among authors: stevanovic s. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4163-70. doi: 10.1158/1078-0432.CCR-05-2470. Clin Cancer Res. 2006. PMID: 16857787
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Widenmeyer M, et al. Among authors: stevanovic s. Int J Cancer. 2012 Jul 1;131(1):140-9. doi: 10.1002/ijc.26365. Epub 2011 Sep 14. Int J Cancer. 2012. PMID: 21858810 Clinical Trial.
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H. Walter S, et al. Among authors: stevanovic s. Nat Med. 2012 Aug;18(8):1254-61. doi: 10.1038/nm.2883. Epub 2012 Jul 29. Nat Med. 2012. PMID: 22842478 Clinical Trial.
Towards patient-specific tumor antigen selection for vaccination.
Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanović S. Rammensee HG, et al. Among authors: stevanovic s. Immunol Rev. 2002 Oct;188:164-76. doi: 10.1034/j.1600-065x.2002.18815.x. Immunol Rev. 2002. PMID: 12445290 Review.
454 results